19 Oct 18
Life Science Analysis: RNA therapeutics are now a clinical reality
After nearly two decades in development, RNA therapeutics are now a clinical reality.
Shore Capital’s Healthcare Analyst, Tara Raveendran, discusses how the approval of these RNA-based therapeutics marks the start of the next chapter in what has been a rollercoaster ride for this novel
18 Oct 18
Shore Capital appointed as Joint Broker to Marks & Spencer plc
Shore Capital is delighted to have been appointed as Joint Broker to the FTSE 100 retailer, Marks & Spencer plc.
For further information please contact:
Hugh Morgan / Edward Mansfield (Corporate Advisory)
Malachy McEntrye (Corporat